Regulatory Considerations and Trends Europe and the U.S.
|
|
- Bartholomew Moody
- 6 years ago
- Views:
Transcription
1 Regulatory Considerations and Trends Europe and the U.S. Professor Kjell Strandberg MD PhD Chairman NDA Advisory Board, NDA Regulatory Science Ltd UK Former CPMP Member and Director General Medical Products Agency Sweden Slide 1
2 Outline of Presentation EU and US Perspectives Regulatory Science and Regulatory Strategy Routes for Marketing Authorisation (MA) Review Time Objectives Review Outcomes Scientific Advice and Advisory Committees Notable Between Agency Differences Regulatory Trends Lessons to be Learnt Slide 2
3 No Regulatory Approval No Market Predicting as accurately as possible the approvability of a product/product candidate is imperative Watch out for inflated phase II and III data Obtaining the best labelling possible is important but don t go over board in the effort Marketing activities must not backfire Approval no end of story Diligent life cycle management a necessity AND. Pricing, Reimbursement, Health Tech Assessments Slide 3
4 Regulatory Science Regulatory science constitutes the scientific application of the regulatory requirements to drug development and surveillance to secure that only efficacious and safe drugs are available for use in the health care system (regulator s view) Application of regulatory strategy to the development and maintenance of drugs (industry s view) Slide 4
5 Regulatory Strategy Instruments Legislation Regulatory guidelines and concept positions Regulatory precedents Cross country/atlantic differences Who are the influential regulators and their positions Where and when to seek scientific advice regulator buy-in How to use leading scientific opinion makers Create a good relationship with the regulators no vacuum cleaning apply a win-win approach Slide 5
6 The New Legal Framework Regulation (EC) 726/2204 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency As of 20 November 2005 IN FORCE! Slide 6
7 Routes for Marketing Authorisation in the European Union Centralised procedure(cp) European Medicines Agency EMEA Compulsory and optional products Mutual Recognition procedure (MRP) Products authorised (MRP or NP) in the Community prior to November 20th 2005 Decentralised procedure (DCP) Products for which the centralised procedure is not compulsory National procedure (NP) Products only intended for one market and not obliged to use the centralised procedure Medical devices, not subject to approval Combinations of drug and device, primary action determines classification for drug or device regulatory procedure Slide 7
8 Routes for Marketing Authorisation in the U.S. New Drug Applications (NDAs), Center for Drug Evaluation and Research (CDER) New Chemical Entities (NCEs), Abbreviated NDAs (ANDAs) Generic drug products, Biological products (applications) Biological License Applications (BLAs), CBER Vaccines, Allergens etc Medical Devices, Center for Devices and Radiological Health Premarket notifications (510k) Class I and II CDRH Premarket approval (PMA) Class III Combination products (drug, biologic product and/or device) One lead FDA center primary mode of action determines One application or separate applications Orphan drugs, Orphan Drug Office Slide 8
9 Eligibility to Centralised Procedure From November 20 th 2005 Compulsory for Biotech. Compulsory for AIDS, Cancer, Neurodegenerative disorder, Diabetes (EMEA/ /2005) Compulsory for orphan drugs Optional for other NCEs and Generics Optional for existing compounds if significant innovation or if in the interest of patients at the Community level From May 20 th 2008 Compulsory for auto-immune diseases and viral diseases Slide 9
10 Review Times for Marketing Authorisation in the European Union Centralised procedure (CP) Mandatory review times Maximum CHMP Standard Review Time: 210 days Maximum CHMP Accelerated Review Time: 150 days Day 120 CHMP Assessment Report clock stop Additional clock stops possible (Day 150 and Day 180) Mutual Recognition procedure (MRP) Review time at the discretion of the Reference Member State (RMS) but agencies try to review within 210 days. The MRP to follow may include 1-24 Member States. To be concluded within 90 days. Withdrawal possible arbitration by CHMP likely Decentralised procedure (DCP) Mandatory review times Max RMS Time: 210 days with presentation to Member States after 85 and 120 days. If no resolution arbitration by CHMP Slide 10
11 Review Objectives for Marketing Authorisation in the U.S. Standard NDAs Action on 90% within 10 months Action on 100% within 12 months Priority NDAs Action on 90% within 5 months Action on 100% within 6 months Note that NDAs include all applications for pharmaceuticals, e.g. new dosage forms, new formulations, new indications Slide 11
12 Agency Responses to a Marketing Authorisation Application (MAA) in the EU and the U.S. Centralised Procedure FDA Action Day 120 CHMP Assessment Report Assessment Report (AR) - Approvable - Approved No major objections but points for but usually with some clarification to be dealt with in the post-approval next AR Day 150 commitments (PAC) - Non-approvable - Approvable but Major objections that preclude MA pre- and/or post AC must be dealt with in 3 (6) - Non-approvable months. Unless prior agreement Major deficiencies should no new data is accepted be addressed pre-post AC - Positive or Negative Opinion Day 210 Slide 12
13 The U.S. Not Approvable Letter to the Applicant Possible Actions 1. Within 10 days amend the application or notify the FDA of an intent to file an amendment Constitutes an agreement by the applicant to extend the review period. Failure to respond within 10 days = request for withdrawal 2. Withdraw the application 3. Request a hearing about the grounds for denying approval 4. Agree with FDA on the length of the extension period Failure to respond adequately within the extension period = request for withdrawal of the application = Not approved Slide 13
14 The Regulatory Environment EU approvals for NCEs in 2005 for Top Pharma Companies Rotarix Macugen Xolair Noxafil GSK Pfizer Merck Astra- Zeneca Aventis BMS Wyeth J&J Novartis Lilly 0 Schering- Plough Source: EMEA plus company web-sites March 2006 Slide 14
15 The Regulatory Environment Applications and Opinions 2005 in the Centralised Procedure Number of applications 40 (A:6, B:34); (2004:42) (A:17, B:25) Whereof orphan drugs: 21 (52%)!! and Number of positive opinions: 24 (2004: 31) Whereof NCEs:13 (A:5, B:8); (2004: 19) Whereof orphan drugs: 2 (+1 non-nce) (2004: 5) Withdrawals: 11 (35%) + 1 neg. opinion; A:0, B:12 Approval time:7+1+clock stop months=11-14 months Slide 15
16 The Regulatory Environment CDER Median Review and Approval Times for Priority and Standard NMEs and BLAs Priority Standard Year n Review Approval n Review Approval Note: Many more priority approvals in the U.S. vs EU but similar approval times. Much longer approval times for standard MAAs in the U.S. Less than 50% approved in first round. Slide 16
17 Reasons for Failure Major Objections at Day 120 Reasons for ultimate rejection Efficacy 60 % 40 Quality Pre-clinical Safety 20 0 Slide 17
18 Agency Advice on Development Plans and Submissions; Use of Advisory Committees EMEA FDA Scientific Advice Working Party The Therapeutic Area Division - Development plans (any stage) - Pre-IND meeting, the - Risk Management Plan clinical development plan - Protocol Assistance orphan drugs - Protocol Assessment - End of Phase 2 meeting The Secretariat Additional meetings possible - Pre-submission meeting - Pre-NDA meeting Scientific Advisory Groups (SAGs) Advisory Committees - Advice to CHMP on MAAs - Advice to FDA on MAAs National agencies also give advice Slide 18
19 Agency Advice on Development Plans and Submissions; Impact on Outcome is an indispensable tool for getting things right increase the likelihood of successful MAAs the earlier in the development program the better do ask the critical questions about efficacy and safety but also ask some general questions to find out the overall agency impression of the development program and its adequacy for a submission global development necessitates regional advice make selective use of EU national agency advice Slide 19
20 Impact of Scientific Advice on proportion of approvals over time EMEA Annual Report Slide 20
21 Notable Differences between the U.S. and EU agency operations General guidelines for quality, efficacy and safety are the same (ICH) but therapeutic area guidelines may differ substantially FDA require more data and review bottom-up whereas EU review top-down Major Resource Difference EU generally require comparative studies whereas FDA may be satisfied with placebo control data Thus the design and/or the review of the development program may be satisfactory to one agency and not to the other Where EU have experts the FDA have divisions with different impact on consistency and decision-making The FDA regulate drugs and devices provided separately but used together. In the EU such devices are regulated separately according to the less demanding Medical Device directive Slide 21
22 The Regulatory Environment Regulatory Fear and Regulatory Creep The introduction of new principles for treatment acting on the immune system or on completely new targets and intended for chronic treatment have resulted in Longer duration of studies More patients in the database More post-approval commitments/conditions 2nd/3rd line indications, restrictions for special populations In addition comparative studies are required for almost all new drugs - and a Risk Management Plan because Immense sensitivity for safety issues VIOXX, TYSABRI, TGN1412 ( The superantibody ) Slide 22
23 The Regulatory Environment Co-operation between EMEA and FDA Implementation plan concluded 16 th September 2004, program extended for 5 years end of 2005 Exchange of draft legislations Educational programme Exchange of information on critical issues relating to evaluation of MA applications and post-approval safety Parallel scientific advice, i.e. end of phase II meetings for break-through products, orphan drugs etc International Conference on Harmonisation (ICH) Slide 23
24 The Regulatory Environment Lessons to be Learnt The Need for a Regulatory Strategy starts with the first promising study results that make you consider drug development. Then you need to answer questions like The target indication? The data required for approval? Regional differences? Recent regulatory precedents? Regulator opinion makers? The competition? Whom to contact and when to know that you are on track? and many more Early regulatory and continous agency advice mandatory for a successful outcome. FIRST ROUND APPROVALS UNIQUE Slide 24
How are medicines evaluated at the EMA
How are medicines evaluated at the EMA Presented by: Nathalie Bere Patient interaction / Stakeholders and communication Division An agency of the European Union The European System Centralised Procedure
More informationMarketing Authorisation Procedures in Europe: A Regulatory Perspective
Available online at http://www.urpjournals.com International Journal of Pharmacy and Pharmaceutical Science Research Universal Research Publications. All rights reserved Review Article Marketing Authorisation
More informationMarketing Authorisation Routes in the EU
Marketing Authorisation Routes in the EU The EU medicines regulatory system and the European Medicines Agency: an introduction for international regulators and non-governmental organisations 18 September
More informationStudy & Comparison of Drug Approval Process for Different Countries in Relation to Authorisation Agency & Clinical Trials
ISSN 0976 3333 Available Online at www.ijpba.info International Journal of Pharmaceutical & Biological Archives 2017; 8(6): 25-30 REVIEW ARTICLE Study & Comparison of Drug Approval Process for Different
More informationApplying for EU marketing authorisation. For medicinal products for human use. An agency of the European Union
Applying for EU marketing authorisation For medicinal products for human use An agency of the European Union Medicines can be authorised throughout the EU by means of a single application procedure. The
More informationThis video gives an overview of the centralised procedure at the European Medicines Agency
This video gives an overview of the centralised procedure at the European Medicines Agency In Europe today, all medicines must have a marketing authorisation before they can be used by patients And there
More informationThe European Medicines Agency: a model of patient/consumer interaction
The European Medicines Agency: a model of patient/consumer interaction V International Conference on patient safety Juan García Burgos Head of Public Information and Stakeholder Networking - Medical Information
More informationChapter 28 Pharmaceutical acquis (human and veterinary medicinal products)
Chapter 28 Pharmaceutical acquis (human and veterinary medicinal products) Screening meeting with Serbia 5 December 2014 DG SANTE D5: Medicinal products - authorisations, EMA; D6: Medicinal products -
More informationComparative Study of Regulatory Requirements for Biologics Filing in United States and European Union
Comparative Study of Regulatory Requirements for Biologics Filing in United States and European Union Mr. Shashi Kumar Yadav Assistant Professor Sri Indu Institute of Pharmacy Hyderabad Outline Introduction
More informationThe role of patients at the EMA
The role of patients at the EMA Nathalie Bere Patient relations coordinator / European Medicines Agency An agency of the European Union What is the European Medicines Agency (EMA) The EMA is the EU regulatory
More informationThe role of EMA and drug approvals for chronic HBV/HCV
The role of EMA and drug approvals for chronic HBV/HCV Summit Conference Hepatitis B and C Brussels, 14-15 October 2010 Marco Cavaleri Head of Antiinfectives and Vaccines, Safety&Efficacy Sector, EMA An
More informationChin Koerner Executive Director US Regulatory and Development Policy
Chin Koerner Executive Director US Regulatory and Development Policy Novartis Pharmaceuticals Corporation 1700 Rockville Pike Suite 510 Rockville, MD 20852 Tel 301.468.5607 Fax 301.468.5614 Email: Chin.Koerner@novartis.com
More informationDeal Making and Product Development in Europe: Changes and Trends You Need to Know About: Regulatory Strategy
Deal Making and Product Development in Europe: Changes and Trends You Need to Know About: Regulatory Strategy Lincoln Tsang Amanda Wearing Jeremy Willcocks November 19, 2004 November 19, 2004 Slide 1 Key
More informationCMD(h) GUIDANCE FOR MAHs ON THE PHARMACOVIGILANCE SYSTEM AND RISK MANAGEMENT PLAN IN THE MUTUAL RECOGNITION & DECENTRALISED PROCEDURES
CMD(h) GUIDANCE FOR MAHs ON THE PHARMACOVIGILANCE SYSTEM AND RISK MANAGEMENT PLAN IN THE MUTUAL RECOGNITION & DECENTRALISED PROCEDURES 1. INTRODUCTION (BACKGROUND) November 2007 According to Article 8
More informationCOMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) GUIDELINE ON REQUIREMENTS FOR VACCINE ANTIGEN MASTER FILE (VAMF) CERTIFICATION
The European Agency for the Evaluation of Medicinal Products Pre-authorisation Evaluation of Medicines for Human Use London, 17 March 2005 EMEA/CPMP/4548/03/Final/Rev 1 COMMITTEE FOR PROPRIETARY MEDICINAL
More informationIntroduction to the European Medicines Agency
Introduction to the European Medicines Agency EFA training for patient experts on allergy, asthma and COPD on getting involved with the EMA, 18 February 2014 Presented by: Isabelle Moulon Head of patients
More informationRegulatory Affairs: Study Report of New Drug Registration Process in European Union
95 Review Article Regulatory Affairs: Study Report of New Drug Registration Process in European Union Yogeshkumar B. Viradiya*, Manoj B. Dagwar, Swapnil T. Lanjewar Department of Regulatory Affairs, Institute
More informationPreparing for the withdrawal is therefore not just a matter for EU and national authorities, but also for private parties.
19 June 2018 CMDh/361/2017, Rev.2 Questions and Answers related to the United Kingdom's withdrawal from the European Union with regard to national authorised medicinal products for human use Introduction
More informationRegulatory Requirements for the Drug Approval Process in US, Europe and India
Regulatory Requirements for the Drug Approval Process in US, Europe and India Jawahar.N 1 *, Vidhya Lakshmi. T 2 1 Department of Pharmaceutics, 2 Pharmaceutical Drug Regulatory Affairs Division, JSS College
More informationContent. Introduction: Approval of ATMPs. Support to ATMP developers. Role of EMA and National Competent Authorities
Content Introduction: Role of EMA and National Competent Authorities Approval of ATMPs What are ATMPs? Centralised procedure Support to ATMP developers 1 Introductory statements This talk is on marketing
More informationAccelerated Approvals
Accelerated Approvals An Industry Perspective Kumeshnie Padayachee University of Pretoria 09 September 2015 Table of Contents ZA Expedite Review Process Fast Track Overview of FDA Expedited Pathways: Focus
More informationVariation Regulations (EU)
Variation Regulations (EU) Headlines of the Update APIC c view Hilde Vanneste APIC Task Force leader Hilde.Vanneste@its.jnj.com 1 Content Scope of regulation: Type of procedures and hence 2 strands Current
More informationReport from the Paediatric Committee on its first anniversary
European Medicines Agency London, 11 July 2008 Doc. Ref. EMEA/PDCO/347884/2008 Report from the Paediatric Committee on its first anniversary The European Medicines Agency s Paediatric Committee (PDCO)
More informationKey concepts of the paediatric regulation and latest developments
Key concepts of the paediatric regulation and latest developments Paolo Tomasi, M.D. Ph.D. Head of Paediatric Medicines European Medicines Agency Presented by: Paolo Tomasi An agency of the European Union
More informationToxicology - Problem Drill 24: Toxicology Studies in Pharmaceutical Development
Toxicology - Problem Drill 24: Toxicology Studies in Pharmaceutical Development No. 1 of 10 1. regulates all the drugs products manufactured and sold in the USA. (A) EMEA (B) IND (C) FDA (D) NDA (E) OSHA
More informationORPHAN DESIGNATION BY THE EMA. Paillard Juliette M2 AREIPS 15/11/2016
ORPHAN DESIGNATION BY THE EMA Paillard Juliette M2 AREIPS 15/11/2016 Legal basis 1. Legal background 2. Criteria SUMMARY Procedure 1. Prior to the submission 2. Submission and validation 3. Evaluation
More informationEU scientific regulatory support mechanisms and initiatives for innovation in drug development: the EMA perspective
EU scientific regulatory support mechanisms and initiatives for innovation in drug development: the EMA perspective FAMHP Workshop, Brussels, 2 nd May 2016 Presented by Zahra Hanaizi Product Development
More informationPhasing-in EU procedures: MRP and referrals September 23, 2003
This document sets out discussions held in the PERF III Acquis Group. It intends to facilitate preparation and implementation of the relevant EC legislation. The document is of an informal character only
More informationREGULATORY ANALYSIS OF THE VARIATION PROCEDURES OF MEDICINAL PRODUCTS AFTER THE EU ACCESSION OF BULGARIA FOR THE PERIOD
Article HTTP://DX.DOI.ORG/10.5504/BBEQ.2013.0028 pb PHARMACEUTICAL BIOTECHNOLOGY REGULATORY ANALYSIS OF THE VARIATION PROCEDURES OF MEDICINAL PRODUCTS AFTER THE EU ACCESSION OF BULGARIA FOR THE PERIOD
More informationThe European Agency for the Evaluation of Medicinal Products Work Programme 2003
The European Agency for the Evaluation of Medicinal Products Work Programme 2003 Adopted by the Management Board on 19 December 2002 The Work Programme for 2003 is presented by the Executive Director to
More informationCommission's proposal to review EU pharmaceutical legislation
SPEECH/01/354 Mr Erkki Liikanen Member of the European Commission, responsible for Enterprise and the Information Society Commission's proposal to review EU pharmaceutical legislation Press conference
More informationRequerimientos para la Exportation
Requerimientos para la Exportation Registro de Productos Farmacéuticos en Países que Adoptaron el CTD Check List de contenidos fundamentales del CTD Requerimientos para la Exportation GAP y Fortalezas
More informationScientific advice and its impact on marketing authorisation application reviews
Scientific advice and its impact on marketing authorisation application reviews SME info day: Tools to support innovative medicines development and early access Presented by Jan Regnström, MD, PhD Scientific
More informationSupporting Innovation through Scientific Advice
Supporting Innovation through Scientific Advice PEARRL Regulatory Science Symposium, 21 st June 2017, University College Cork HPRA Dr Peter Kiely Disclaimer All views expressed in this presentation are
More informationWriting an Assessment Report
Safeguarding public health Writing an Assessment Report Name: Malcolm Dash Date: Programme Why we need Assessment Reports Writing style Deficiency points Potential Serious Risk to Public Health Targeted
More informationA SHORT GUIDE TO THE PROCEDURE FOR A CLINICAL TRIAL APPLICATION IN THE KINGDOM OF BAHRAIN
A SHORT GUIDE TO THE PROCEDURE FOR A CLINICAL TRIAL APPLICATION IN THE KINGDOM OF BAHRAIN Version 1 - June 2017 A Short Guide For CT Application 1 2 A Short Guide For CT Application DEFINITIONS Clinical
More informationNew Regulation for Advanced Therapies including Oncology Biological Products. isbtc Global Regulatory Summit
New Regulation for Advanced Therapies including Oncology Biological Products isbtc Global Regulatory Summit Patrick Celis, PhD European Medicines Agency (EMEA) Presentation Overview EMEA and the European
More informationClinical Trials A Closer Look
The Food and Drug Administration (FDA) is the main consumer watchdog for numerous products: Drugs and biologics (prescription and over-the counter) Food Medical devices Animal feed and drugs Cosmetics
More informationRegulatory Challenges of Global Drug Development in Oncology. Jurij Petrin, M.D. Princeton, NJ
Regulatory Challenges of Global Drug Development in Oncology Jurij Petrin, M.D. Princeton, NJ Topics General global R&D issues Regulatory issues with global oncology drug development US FDA initiatives
More information24/11/2010. Dr. Anja Holm Chair of CVMP. Committee for Medicinal Products for Veterinary Use, European Medicines Agency
Mutual Recognition Procedure in Europe Dr. Anja Holm Chair of CVMP Vaccines Committee for Medicinal Products for Veterinary Use, European Medicines Agency Danish Medicines Agency Copenhagen, Denmark anh@dkma.dk
More information13 May 2010 BY . Subject: Comments on the Concept Paper on the Revision of the Clinical Trials Directive 2001/20/EC
13 May 2010 BY E-MAIL Reference: DSanco11003 sanco-pharmaceuticals@ec.europa.eu European Commission Directorate General for Health and Consumers (SANCO) B-1049 BRUSSELS Subject: Comments on the Concept
More informationGuidance for Industry
Guidance for Industry Submission of Abbreviated Reports and Synopses in Support of Marketing Applications U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation
More informationDrug Development & the FDA Pharmacy 309 November 2005
Goals & Objectives Drug Development & the FDA Pharmacy 309 November 2005 Tom Hazlet, Pharm.D., Dr.P.H. H375S 206.616.2732 thazlet@u... Be able to describe major regulatory events in the drug & biologic,
More informationRevision of the Variations Regulation. Key Principles and Guidelines Development CONTENT
DIA/EMEA/CMD(h) Conference London 26 October 2009 Revision of the Variations Regulation - Key Principles and Guidelines Development Hilde Boone EMEA 1 1 CONTENT 1. Background & revision status 2. Types
More informationExplanatory note on general fees payable to the European Medicines Agency
Explanatory note on general fees payable to the European Medicines Agency The fees, fee exemptions and definitions described in this explanatory note apply as of 1 June 2017 and are based on Council Regulation
More informationVOLUME 2A Procedures for marketing authorisation CHAPTER 2 Mutual Recognition. February 2007
EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL Consumer goods Pharmaceuticals Brussels, ENTR/F2/ BL D(2005) NOTICE TO APPLICANTS Revision 5 VOLUME 2A Procedures for marketing authorisation CHAPTER
More informationPerformance indicators for the EMEA in 2003
The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use, rev.1 London, 16 April 24 Performance indicators for the EMEA in 23 7 Westferry Circus, Canary Wharf,
More informationFirst in Human Clinical Trials of medicines
First in Human Clinical Trials of medicines Martin O Kane Head, Clinical Trials Unit, MHRA Topics MHRA Clinical Trials Unit Clinical Trials Legislation Assessment of a clinical trial and FIH considerations
More information-Regulation (EC) No.1394/2007 -Regulation (EC) No. 668/2009
Introduction to Advanced Therapy Medicinal Products Regulation -Regulation (EC) No.1394/2007 -Regulation (EC) No. 668/2009 -Directive 2009/120/EC Dr. Maura O Donovan F.R.C.O.G. MA MD M.R.C.P.I. CAT member
More informationHTAs and EMA working together: 23 parallel scientific advice procedures later - what have we learned?
HTAs and EMA working together: 23 parallel scientific advice procedures later - what have we learned? DIA 26th Annual EuroMeeting, Vienna 2014 Jan Regnstrom, MD, PhD Senior Scientific Officer An agency
More informationLaunching drug product in Europe Q&A
Launching drug product in Europe Q& David McCoubrey: Senior Regulatory ffairs Scientist, lmac Group Q& Launching drug product in Europe Q& David McCoubrey: Senior Regulatory ffairs Scientist, lmac Group
More informationEMA/CAT support to ATMP developers
EMA/CAT support to ATMP developers CAT-ISCT Workshop: Challenge and opportunities for the successful development and approval of Advanced Therapy Medicinal Products. Presented by Patrick Celis on 25 September
More informationClinical Development and enabling Regulatory Steps: How to obtain ODD and Scientific Advice at EMA
Clinical Development and enabling Regulatory Steps: How to obtain ODD and Scientific Advice at EMA TELETHON Convention, Riva del Garda (TN) 15 March 2017 Michela Gabaldo Head Alliance Management & Regulatory
More informationIssues identified by stakeholders: follow-up from EMA s ATMP workshop
2 February 2017 EMA/48099/2017 Human Medicines Research and Development Support Division On 27 May 2016 EMA hosted a workshop 1 aimed to foster ATMP development and enable expanded patient access in the
More informationAccession Preparation: Situation in Croatia
Accession Preparation: Situation in Croatia Siniša Tomić, PhD, Associate Professor Head of the Agency for Medicinal Products and Medical Devices (HALMED), Croatia Content: Croatian Agency for Medicinal
More informationRegulations of Biologics in Taiwan
Regulations of Biologics in Taiwan Churn-Shiouh Gau, Ph.D. Executive Director, Taiwan 2013/2/13 1 Outlines Regulation of Drugs in Taiwan - Organizations Regulations for Marketing Approval for Drugs including
More informationThe 23 rd Autumn Introductory Course:
The 23 rd Autumn Introductory Course: Target the Heart of European Regulatory Affairs Prague, Czech Republic Sheraton Prague Charles Square hotel Zitna 561/8, Prague 13-17 November 2017 Monday 13 November
More informationEMA and international cooperation
EMA and international cooperation The EU medicines regulatory system and the European Medicines Agency: an introduction for international regulators and non-governmental organisations London, 18-19 September
More informationExplanatory note on general fees payable to the European Medicines Agency
Explanatory note on general fees payable to the European Medicines Agency The fees, fee exemptions and definitions described in this explanatory note apply as of 1 June 2017 and are based on Council Regulation
More informationConducted Under an IND to Support a
Using Foreign Clinical Trial Data not Conducted Under an IND to Support a US Application PDA Midwest Chapter Meeting March 15, 2018 2013 2017 Regulatory Compliance Associates Inc. All Rights Reserved.
More informationCommission notice on the application of Articles 3, 5 and 7 of Regulation (EC) No 141/2000 on orphan medicinal products (2016/C 424/03)
18.11.2016 EN Official Journal of the European Union C 424/3 Commission notice on the application of Articles 3, 5 and 7 of Regulation (EC) No 141/2000 on orphan medicinal products (2016/C 424/03) A. INTRODUCTION
More informationAdoption by CHMP for release for 3-month public consultation 18 November End of consultation (deadline for comments) 28 February 2011
18 October 2012 EMA/651649/2010 Committee for Medicinal Products for Human Use Reflection paper on considerations given to designation of a single stereo isomeric form (enantiomer), a complex, a derivative,
More informationOfficial Journal C 223. of the European Union. Information and Notices. Information. Volume 56 2 August English edition
Official Journal of the European Union ISSN 1977-091X C 223 English edition Information and Notices Volume 56 2 August 2013 Notice No Contents Page Information INFORMATION FROM EUROPEAN UNION INSTITUTIONS,
More informationOrphan Medicinal Products
Development process of Orphan Medicinal Products 1 Did you know that... A rare disease is officially defined as a lifethreatening or chronically debilitating condition that affects no more than 5 in 10,000
More informationEU regulatory tools for expedited antibacterial development programmes
EU regulatory tools for expedited antibacterial development programmes Expediting antibacterial development: core lessons key tools for a rocky road, ECCMID 2018, Madrid Presented by Marco Cavaleri on
More informationHow CAT Works: Regulatory Process, Patient Contribution and Outcomes
www.eurordis.org How CAT Works: Regulatory Process, Patient Contribution and Outcomes Michele Lipucci Di Paola AVLT/EURORDIS CAT/EMA Patient Representative michele.lipucci@eurordis.org EURORDIS MEMBERSHIP
More informationProduced by the VMD & HPRA. Revised 9th January 2015
Joint-labelling of product literature between the UK and Ireland for Nationally Authorised & Mutually Recognised Veterinary Products: Guidance for the Pharmaceutical Industry Produced by the VMD & HPRA
More informationCentralised Procedure and Scientific Advice: an Overview
Centralised Procedure and Scientific Advice: an Overview Andrea Laslop Head of Scientific Office AGES Medizinmarktaufsicht AGES Vienna 30/01/2018 Austrian Federal Office for Safety in Health Care www.basg.gv.at
More informationRegulatory update from Europe:
Regulatory update from Europe: Procedures to promote early access of medicinal products to the market Elmer Schabel MD Regulatory update from Europe - Overview Current tools for early access Conditional
More informationComment by the Federal Institute for Drugs and Medical Devices in coordination with the Paul Ehrlich Institute and the Federal Ministry of Health
Comment by the Federal Institute for Drugs and Medical Devices in coordination with the Paul Ehrlich Institute and the Federal Ministry of Health on the public consultation 1 ASSESSMENT OF THE FUNCTIONING
More informationEUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL
Ref. Ares(2013)2581479-05/07/2013 EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Health systems and products Medicinal products authorisations, EMA Brussels, date ENTR/6283/00 Rev 4 orphan\guidelines\format
More informationOrphan Drug Designation within the Development Strategy
Case Report imedpub Journals http://wwwimedpub.com Journal of Rare Disorders: Diagnosis & Therapy Vol. 1 No. 2:12 DOI: 10.21767/2380-7245.100012 Orphan Drug Designation within the Development Strategy
More informationHow to put together an IND application
How to put together an IND application Judit Milstein, Chief, Project Management Staff Judit.milstein@fda.hhs.gov Eithu Lwin, Regulatory Health Project Manager Eithu.Lwin@fda.hhs.gov Division of Transplant
More informationGUIDANCE FOR SPONSORS, INDUSTRY, RESEARCHERS, INVESTIGATORS, AND FOOD AND DRUG ADMINISTRATION STAFF
GUIDANCE FOR SPONSORS, INDUSTRY, RESEARCHERS, INVESTIGATORS, AND FOOD AND DRUG ADMINISTRATION STAFF Certifications To Accompany Drug, Biological Product, and Device Applications/Submissions:Compliance
More informationStructure and Mandate of FDA
Structure and Mandate of FDA Leonard Sacks, M.D. Office of Medical Policy Center for Drug Evaluation and Research FDA FDA Clinical Investigator Training Course November 13, 2018 Mission of regulatory agencies
More informationOrphan designation in the EU
Orphan designation in the EU Workshop with Japanese Pharmaceutical Industry 19 September 2013, London Presented by: Jordi Llinares Head of Product Development Scientific Support An agency of the European
More informationPharmacovigilance proposals: patient safety is at risk
European Commission Pharmacovigilance proposals: patient safety is at risk HAI Europe Seminar 23 rd of October 2009 Florence Vandevelde 1960: Thalidomide About 2 500 cases in Germany politicolnews.com
More informationExplanatory note on fees payable to the European Medicines Agency
30 March 2015 EMA/167155/2014 Executive Director Explanatory note on s payable to the European Medicines Agency The s, exemptions and definitions described in this Explanatory Note apply as of 1 April
More informationDRAFT MOTION FOR A RESOLUTION
European Parliament 2014-2019 Committee on the Environment, Public Health and Food Safety 9.3.2017 2017/0000(RPS) DRAFT MOTION FOR A RESOLUTION pursuant to Rule 106(2), (3) and (4)(c) of the Rules of Procedure
More informationRecommendation on elements required to support the medical plausibility and the assumption of significant benefit for an orphan designation
2 March 2010 EMA/COMP/15893/2009 Final Committee for Orphan Medicinal Products (COMP) Recommendation on elements required to support the medical plausibility and the assumption of significant benefit for
More informationComparison of the Non-patent Drug Exclusivities Available in the United States, Canada, Europe and Japan
Comparison of the Non-patent Drug Exclusivities Available in the United States, Canada, Europe and Japan The International Economic Forum of the Americas Serge Lapointe, Ph.D. Partner, Patent Agent June
More informationDivision of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, rm Rockville, MD 20852
Reference No.: FDAA10017 Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, rm. 1061 Rockville, MD 20852 VIA WEB SUBJECT: Approval Pathway for Biosimilar and Interchangeable
More informationBrexit Guidance for Stakeholders Human and veterinary medicines
Brexit Guidance for Stakeholders Human and veterinary medicines DATE: 03 JANUARY 2018 V.2 This guide does not purport to be an interpretation of law and/or regulations. The content provided is subject
More informationReform of Biological Products Review with a Focus on CMC
Reform of Biological Products Review with a Focus on CMC Office of Pharmaceutical Science of Biological Products Center for Drug Evaluation (CDE) of CFDA Min Li WCBP, Jan 2018 Outline Background of Drug
More informationQUESTIONS AND ANSWERS ON MRP & DCP AND EU ENLARGEMENT
QUESTIONS AND ANSWERS ON MRP & DCP AND EU ENLARGEMENT Doc. Ref.: CMDh/274/2012, Rev3 NovemberRev4 December 2012 QUESTIONS AND ANSWERS ON MRP & DCP AND EU ENLARGEMENT... 1 Where can guidance and recommendations
More informationLegislative Framework and Scientific Guidance in European Assessment
Legislative Framework and Scientific Guidance in European Assessment Riccardo Luigetti Quality Assessors Training London 26 October 2009 1 Content of the presentation Scientific guidelines Other related
More informationGuidelines. of
EUROPEAN COMMISSION Brussels, 16.05.2013 C (2013) 2804 Guidelines of 16.05.2013 on the details of the various categories of variations, on the operation of the procedures laid down in Chapters, a, I and
More informationOptimising early access tools: Revision of the guidelines on Accelerated Assessment and Conditional Marketing Authorisation
Optimising early access tools: Revision of the guidelines on Accelerated Assessment and Conditional Marketing Authorisation High-level overview of comments received during the public consultation Presented
More informationEuropean Medicines Agency Perspective
European Medicines Agency Perspective WMA Workshop on revision of DoH, 4-6 Dec 2012, Capetown, South Africa. Presented by: Fergus Sweeney, PhD Head of Sector, Compliance and Inspection, European Medicines
More informationEuropean Union (EU) Regulatory Trends in GMP. Clive Brading Tianjin, China September 23, 2009
European Union (EU) Regulatory Trends in GMP Clive Brading Tianjin, China September 23, 2009 -2- Presentation Topics EU Background Inspections outside the EU EMEA Inspection Outcomes Dedicated Facilities
More informationQUESTIONS AND ANSWERS ON THE PAEDIATRIC REGULATION (REGULATION OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL (EC) No 1901/2006, AS AMENDED)
QUESTIONS AND ANSWERS ON THE PAEDIATRIC REGULATION (REGULATION OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL (EC) No 1901/2006, AS AMENDED) ARTICLE 45 & 46 October 2007 Revision 4, November 2008 Question
More informationEuropean reflections on reviewing NDAs and ANDAs for ICH Q3D elemental impurity compliance
European reflections on reviewing NDAs and ANDAs for ICH Q3D elemental impurity compliance Diana van Riet-Nales, Medicines Evaluation Board/NL NL CHMP/CVMP Quality Working Party delegate (humans) Former
More informationImpurities in Drugs: Monitoring, Safety and Regulation The Israel Chapter of PDA
Overview of exploratory INDs Impurities in Drugs: Monitoring, Safety and Regulation The Israel Chapter of PDA July, 15 16, 2008 David Jacobson-Kram, Ph.D. DABT Office of New Drugs Center for Drug Evaluation
More informationGVP Module X - additional monitoring of medicines
GVP Module X - additional monitoring of medicines 6 th Stakeholders forum on the implementation of the new pharmacovigilance legislation Mick Foy, Group Manager - MHRA An agency of the European Union Contents
More informationOphthalmology Workshop EMA October The orphan perspective. Presented by: Dr Stelios Tsigkos
Ophthalmology Workshop EMA 27-28 October 2010 The orphan perspective Presented by: Dr Stelios Tsigkos Scientific Administrator Human Medicines Special Areas Orphan Drugs Section, EMA European Medicines
More informationNew drug approvals in six major authorities : Focus on the availability of medicines and company size
Median approval time (days) New drug approvals in six major authorities 28 -: Focus on the availability of medicines and size Major improvements in the regulatory environment as well as changes in strategies
More informationBelgium, a European leader in clinical trials
Belgium, a European leader in clinical trials An attractive country for clinical trials to test innovative medicines In Europe it is nearly impossible to find other countries with as many clinical trials
More informationUse of immunotherapy for cancer treatment
Use of immunotherapy for cancer treatment Pre- and post-licensing considerations Professor Angela Thomas, Pediatric Hematologist Vice Chair Commission on Human Medicines Chair Clinical Trials, Biologicals
More informationACG Public Forum. Join ACG, the FDA, and EMA for a discussion on biosimilars and IBD. Monday, 12:45 pm 2:15 pm
ACG Public Forum Join ACG, the FDA, and EMA for a discussion on biosimilars and IBD Monday, 12:45 pm 2:15 pm ACG 2017: FDA-EMA workshop on biosimilars Joachim Musaus EMA Product Lead Gastroenterology Human
More informationINTRODUCTION OF FEES TO BE CHARGED BY THE EMA FOR PHARMACOVIGILANCE
Ref. Ares(2012)723154-18/06/2012 EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Health systems and products Medicinal products authorisations, EMA Brussels, D(2012) INTRODUCTION OF FEES TO
More information